BOL-DP-o-08

BOL-DP-o-08 is a cannabinoid-based investigational drug developed by Breath of Life International Pharma (BOL Pharma) for the treatment of endometriosis. It acts as a modulator of cannabinoid receptors and was designed to be administered sublingually in the form of drops. The drug reached preclinical and early clinical development stages, with plans for a phase IIa randomized, double-blind, placebo-controlled trial in patients with stage 2–4 endometriosis. However, this trial was withdrawn prior to enrollment due to external factors such as the COVID-19 pandemic. The mechanism of action involves modulation of cannabinoid receptors (CB), which are implicated in pain regulation and inflammation—key aspects relevant to endometriosis pathology[1][2][3][5].